TITLE

Cephalon Maintains CIMA Takeout Will Fly

AUTHOR(S)
Cohen, Judy Radler
PUB. DATE
April 2004
SOURCE
Mergers & Acquisitions Report;4/12/2004, Vol. 17 Issue 15, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
Discusses the status of the acquisition deal between Cephalon Inc. and CIMA Laboratories Inc. Amount of money involved in the deal; Tender offer of Cephalon Inc. for the shares of CIMA; Information on the two fentanyl products from CIMA Laboratories Inc. that Cephalon Inc. wants to acquire; Issues that may derail the deal.
ACCESSION #
12805813

 

Related Articles

  • Cephalon to acquire Cima Labs for $515 million.  // PharmaWatch: Biotechnology;December 2003, Vol. 2 Issue 12, p22 

    Reports on the plan of Cephalon Inc. to acquire Cima Labs Inc. in the U.S. Value of deal; Terms under the planned acquisition; Benefits of the acquisition for both companies.

  • SDC Worldwide Mergers & Acquisitions.  // Mergers & Acquisitions Report;9/8/2003, Vol. 16 Issue 34, p6 

    Provides an update on several merger and acquisition deals of companies worldwide as of September 8, 2003. CIMA Labs Inc. and Cephalon Inc.; JNI Corp. and Applied Micro Circuits Corp.; Jacksonville Bancorp and Franklin Bank Corp.

  • Other News To Note.  // BioWorld Today;10/25/2010, Vol. 21 Issue 206, p2 

    This section offers news briefs concerning the biotechnology sector as of October 25, 2010. Cephalon Inc. decided to use its option to purchase BioAssets Development Corp. A 5 million dollar milestone payment was received by Depomed Inc. from Janssen Pharmaceutica N.V. A tender offer of 14.25...

  • Cephalon Continues Spending Spree with $207M Arana Offer.  // BioWorld Today;3/2/2009, Vol. 20 Issue 39, p3 

    The article reports on the continuing spending spree of Cephalon Inc. The company moved to acquire Arana Therapeutics Ltd., a maker of TNF-blocking antibody in Phase II trials for psoriasis and rheumatoid arthritis. Cephalon is offering Australian $318 million for Arana. Cephalon already has...

  • Impax Laboratories initiates patent challenge relating to Generic Fentora.  // PharmaWatch: CNS;Jan2012, Vol. 11 Issue 1, p14 

    The article reports that Cephalon Inc. and CIMA Labs Inc. have filed a lawsuit against Impax Laboratories Inc. on November 18, 2011 for patent infringement with regards to the company's Fentora or fentanyl buccal tablets.

  • CIMA/aaiPharma Tie the Pharmaceutical Knot.  // High Yield Report;8/11/2003, Vol. 14 Issue 32, p1 

    Reports on the proposed merger between U.S.-based pharmaceutical companies aaiPharma and CIMA. Impact of the proposed merger on the financial conditions of the drug manufacturing industry; Estimated capital of the merged companies; Financial standings of the two pharmaceutical companies.

  • Pharma says acquisition is the right prescription. Speizer, Irwin // Business North Carolina;Oct2003, Vol. 23 Issue 10, p22 

    Reports on the merger of drug company aaiPharma Inc. with Cima Labs Inc. in 2003. Basis of the consolidation; Impact of the merger on the companies' stock performance; Changes after the merger.

  • aaiPharma to acquire rival Cima Labs.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p19 

    Reports on the intention of aaiPharma Inc. to acquire Cima Labs Inc. Terms under the deal; Benefits of the agreement for both companies; Significance of the deal for the pharmaceutical biotechnology industry.

  • Par Pharma Buys Three Drugs From Teva. FUGAZY, DANIELLE // Mergers & Acquisitions Report;10/24/2011, Vol. 24 Issue 43, p4 

    The article reports on Teva Pharmaceuticals' sale of the rights to three of its drug products to Par Pharmaceutical Cos. Inc.to avoid conflict related to its acquisition of Cephalon. Terms of the agreement transfer Abbreviated New Drug Applications (ANDAs) for fentanyl citrate lozenges,...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics